These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 27436848)

  • 1. Prognostic role of tumor PIK3CA mutation in colorectal cancer: a systematic review and meta-analysis.
    Mei ZB; Duan CY; Li CB; Cui L; Ogino S
    Ann Oncol; 2016 Oct; 27(10):1836-48. PubMed ID: 27436848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
    Mao C; Yang ZY; Hu XF; Chen Q; Tang JL
    Ann Oncol; 2012 Jun; 23(6):1518-25. PubMed ID: 22039088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
    Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
    Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Jin J; Shi Y; Zhang S; Yang S
    Acta Oncol; 2020 Jan; 59(1):66-74. PubMed ID: 31545109
    [No Abstract]   [Full Text] [Related]  

  • 5.
    Li AJ; Li HG; Tang EJ; Wu W; Chen Y; Jiang HH; Lin MB; Yin L
    World J Gastroenterol; 2018 Feb; 24(5):631-640. PubMed ID: 29434452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic role and clinicopathological features of SMAD4 gene mutation in colorectal cancer: a systematic review and meta-analysis.
    Fang T; Liang T; Wang Y; Wu H; Liu S; Xie L; Liang J; Wang C; Tan Y
    BMC Gastroenterol; 2021 Jul; 21(1):297. PubMed ID: 34301194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior.
    Jang S; Hong M; Shin MK; Kim BC; Shin HS; Yu E; Hong SM; Kim J; Chun SM; Kim TI; Choi KC; Ko YW; Kim JW
    Hum Pathol; 2017 Jul; 65():21-30. PubMed ID: 28188750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
    Nakayama I; Shinozaki E; Matsushima T; Wakatsuki T; Ogura M; Ichimura T; Ozaka M; Takahari D; Suenaga M; Chin K; Mizunuma N; Yamaguchi K
    BMC Cancer; 2017 Jan; 17(1):38. PubMed ID: 28068936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No significant association between PIK3CA mutation and survival of esophageal squamous cell carcinoma: A meta-analysis.
    Ge XQ; Yang YZ; Li SS; Hou L; Ren JL; Yang KP; Fa XE
    J Huazhong Univ Sci Technolog Med Sci; 2017 Jun; 37(3):462-468. PubMed ID: 28585132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis.
    Yang ZY; Wu XY; Huang YF; Di MY; Zheng DY; Chen JZ; Ding H; Mao C; Tang JL
    Int J Cancer; 2013 Oct; 133(8):1914-25. PubMed ID: 23494461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.
    Liao X; Lochhead P; Nishihara R; Morikawa T; Kuchiba A; Yamauchi M; Imamura Y; Qian ZR; Baba Y; Shima K; Sun R; Nosho K; Meyerhardt JA; Giovannucci E; Fuchs CS; Chan AT; Ogino S
    N Engl J Med; 2012 Oct; 367(17):1596-606. PubMed ID: 23094721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Impact and Prognostic Role of KRAS/BRAF/PIK3CA Mutations in Stage I Colorectal Cancer.
    Reggiani Bonetti L; Barresi V; Maiorana A; Manfredini S; Caprera C; Bettelli S
    Dis Markers; 2018; 2018():2959801. PubMed ID: 30018674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations between primary tumor RAS, BRAF and PIK3CA mutation status and metastatic site in patients with chemo-resistant metastatic colorectal cancer.
    Christensen TD; Palshof JA; Larsen FO; Poulsen TS; Høgdall E; Pfeiffer P; Jensen BV; Yilmaz MK; Nielsen D
    Acta Oncol; 2018 Aug; 57(8):1057-1062. PubMed ID: 29380640
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Xu JM; Wang Y; Wang YL; Wang Y; Liu T; Ni M; Li MS; Lin L; Ge FJ; Gong C; Gu JY; Jia R; Wang HF; Chen YL; Liu RR; Zhao CH; Tan ZL; Jin Y; Zhu YP; Ogino S; Qian ZR
    Clin Cancer Res; 2017 Aug; 23(16):4602-4616. PubMed ID: 28424201
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer.
    Domingo E; Church DN; Sieber O; Ramamoorthy R; Yanagisawa Y; Johnstone E; Davidson B; Kerr DJ; Tomlinson IP; Midgley R
    J Clin Oncol; 2013 Dec; 31(34):4297-305. PubMed ID: 24062397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Value of the Glasgow Prognostic Score or Modified Glasgow Prognostic Score for Patients with Colorectal Cancer Receiving Various Treatments: a Systematic Review and Meta-Analysis.
    He L; Li H; Cai J; Chen L; Yao J; Zhang Y; Xu W; Geng L; Yang M; Chen P; Zheng J; Yang Y; Gong S
    Cell Physiol Biochem; 2018; 51(3):1237-1249. PubMed ID: 30481755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.
    Palomba G; Doneddu V; Cossu A; Paliogiannis P; Manca A; Casula M; Colombino M; Lanzillo A; Defraia E; Pazzola A; Sanna G; Putzu C; Ortu S; Scartozzi M; Ionta MT; Baldino G; Sarobba G; Capelli F; Sedda T; Virdis L; Barca M; Gramignano G; Budroni M; Tanda F; Palmieri G
    J Transl Med; 2016 Oct; 14(1):292. PubMed ID: 27737711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer.
    Lee DW; Han SW; Cha Y; Bae JM; Kim HP; Lyu J; Han H; Kim H; Jang H; Bang D; Huh I; Park T; Won JK; Jeong SY; Park KJ; Kang GH; Kim TY
    Cancer; 2017 Sep; 123(18):3513-3523. PubMed ID: 28513830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PIK3CA mutation status, progression and survival in advanced HR + /HER2- breast cancer: a meta-analysis of published clinical trials.
    Fillbrunn M; Signorovitch J; André F; Wang I; Lorenzo I; Ridolfi A; Park J; Dua A; Rugo HS
    BMC Cancer; 2022 Sep; 22(1):1002. PubMed ID: 36131248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of PIK3CA Mutations in Plasma DNA of Colorectal Cancer Patients by an Ultra-Sensitive PNA-Mediated PCR.
    Zeng Q; Xie L; Zhou N; Liu M; Song X
    Mol Diagn Ther; 2017 Aug; 21(4):443-451. PubMed ID: 28247181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.